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SUMMARY
We have studied the effect of dialysates from lung cancer homogenates to alter both the
expression of complement (C3b) receptors per se and also to inhibit leucoattractant-
induced enhancement of complement rosettes on monocytes from healthy individuals.
Enhancement and enhancement-inhibition by tumour extracts were compared with
material derived from normal lung excised some distance from the tumour. There was no
significant difference between tumour homogenate (TH) and normal lung homogenate
(NLH) in terms ofenhancement ofcomplement rosettes per se. In contrast, TH produced
a dose- and time-dependent inhibition of leucoattractant-induced enhancement of C3b
rosettes which was significantly different from that obtained with NLH. This enhance-
ment-inhibition was observed with four undifferentiated, four squamous and three adeno-
carcinomas of lung. The degree of enhancement-inhibition was not related to the type of
tumour or varying accompanying histological features such as necrosis and the degree of
infiltration with inflammatory cells. Following gel filtration on Sephadex G-50 each type
of cancer gave a major peak of inhibitory activity which eluted with molecules having an
apparent molecular size of approximately 3,000 daltons. A second larger peak
(8,000-10,000 daltons) was also detectable with extracts from the undifferentiated and
adenocarcinomas. These results support previous findings, mainly from experimental
animals, indicating that 'anti-macrophage/monocyte principles' are elaborated from
certain tumour types.
INTRODUCTION
It is a widely-held view that cells of the lymphoid series, particularly mononuclear phagocytes, are
principal effector cells in tumour immunity. Although the role of lymphoid cells in immunological
surveillance oftumours in general, and ofmacrophages in particular, is controversial, it seems likely
that some tumours, at some stage in their development, are susceptible to destruction by mononuc-
lear phagocytes. Macrophages are prominent in syngeneic animal tumours (Evans & Alexander,
1972) and, in mice, can inhibit tumour growth when inoculated together with tumour cells (Bennett,
1965). Macrophages can also enhance the inhibition of tumour progression mediated by BCG
(Hopper & Pimm, 1976).
A number of investigators have reported that tumour-derived material from experimentally-
induced neoplasms inhibit macrophage function both in vivo and in vitro. In general, the inhibitory
activity has been associated with molecules having a molecular size of less than 10,000 (Fauve et al.,
1974; North, Kirstein & Tuttle, 1976; Pike & Snyderman, 1976; Nelson & Nelson, 1978; Normann
& Cornelius, 1978). As a result of these observations in animals and studies in man which indicate
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that monocyte locomotion is defective in certain solid tumours such as genito-urinary neoplasms
and malignant melanoma (Boetcher & Leonard, 1974; Hausman et al., 1975), we have attempted to
establish whether human tumours elaborate 'anti-macrophage' principle(s) comparable to those
previously described in mice and rats. We chose to study extracts from lung cancers since fresh
material was readily available and because our previous work indicated that the advanced stage of
this disease was also associated with a defect in the locomotion of peripheral blood monocytes (Kay
& McVie, 1977).
Rather than employing inhibition of monocyte locomotion as our test system we have used a
newly developed assay of monocyte function - complement receptor enhancement (Glass & Kay,
1980). 'Complement receptor enhancement' is the term we have given to increased expression (or
unfolding) of C3b receptors on human leucocytes following incubation with leucoattractants. The
phenomenon was first described with eosinophils and 'eosinophilotactic' agents such as histamine
and ECF-A tetrapeptides (Anwar & Kay, 1977, 1978). However, we have also shown that
complement receptor enhancement is a property of human neutrophils and monocytes following
incubation of these cells with various chemoattractants such as formyl-methionyl peptides, lym-
phokines and casein (Glass & Kay, 1980; Kay, Glass & Salter, 1979). Thus complement receptor
enhancement is induced by leucoattractants and occurs in parallel with cell locomotion. We believe
that this apparent increase in the density of complement receptors may be indicative of a general
biological phenomenon whereby the degree of adhesion ofphagocytic cells to opsonized particles is
increased.
In the present report we provide evidence that dialysates from a number of human lung cancer
homogenates, when compared to dialysates from normal lung, inhibit casein-induced enhancement
ofmonocyte complement receptors. Furthermore, the inhibitory principles appear to have a similar
molecular size to material previously identified from animal tumours and which inhibited macro-
phage chemotaxis.
MATERIALS AND METHODS
Materials
Materials were obtained as follows: casein (BDH Chemicals Ltd, Poole, England); preservative-free
heparin (Evans Medical, Liverpool, England); Ficoll and Hypaque, Sephadex G-50 (Pharmacia,
Uppsala, Sweden).
Methods
Homogenatesfrom lung cancer andnormal lung controls. Fresh surgical specimens were obtained
at thoracotomy and placed directly into sterile plastic bags. A portion of approximately 5 g was
removed from the tumour mass in such a way as not to jeopardize the histological diagnosis. A
portion of normal tissue ofcomparable size to the tumour was taken from the periphery of the lobe
or bronchopulmonary segment. Portions of the normal lung, as well as the tumour mass, were
prepared for routine histopathological sections. The unfixed tissue was either stored at -80°C or
prepared immediately in the following way: samples of tumour, or normal lung, were cut into small
fragments of approximately 200-400 mg and placed in 5-15 ml of PBS. The materials were frozen
and thawed six times, centrifuged at 1,800 g for 10 min to remove particulate matter and the
supernatants dialysed against PBS (twice the volume) for 18 hr at 4°C. The protein concentration of
the dialysates was determined by the Coomassie blue method and the samples divided into portions
of approximately 1 ml and stored at -80°C until use.
The various histological features of the tumours were assessed by two independent pathologists
and graded (0, +, +, + +, + + +) as shown in Table 1. The portions of normal lung from the
periphery of the sections were free of microscopically detectable tumour cells.
Preparation ofEA, EACJ423b and 'EA C'. This has been described in detail elsewhere (Anwar&
Kay, 1977, 1978) and was briefly as follows. Dextrose-gelatin-veronal buffer (DGVB2 , pH 7.4)
was used for washing sheep erythrocytes (E) during sensitization and coating with complement. The
buffer was prepared by mixing equal volumes of isotonic veronal-buffered saline (containing 0-0015
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M Ca2+, 0-0005 M Mg2+ and 0.1% gelatin-veronal buffer, GVB2+) with 5% dextrose in water
containing the same concentration ofCa2+ and Mg2 + The IgM and IgG fractions of rabbit antisera
to sheep red cells (A) were prepared by Sephadex G-200 gel filtration (Shevach et al., 1972). The IgG
fraction was further purified by DEAE-52 anion exchange chromatography (Fahey & Terry, 1978).
Either IgG or IgM was used in the sensitization of E for the preparations of EArab or EArab
respectively. The antibody concentration of EArab selected was that which gave optimal sensitiza-
tion for haemolysis but no agglutination. For the preparation of EAGb, the antibody concentration
was diluted so as to give approximately 30% monocyte rosettes. Functionally pure human comple-
ment components were added sequentially to EA rb to prepare C3b-coated cells (EAC1423b). The
amounts were as follows: 400 effective molecules of CI, 400 of C4, 50 of C2 and 400 of C3. This
amount of C4 was insufficient to give EAC14 rosettes with monocytes (Anwar & Kay, 1978). In
most experiments fresh human AB serum was also used as a source of complement ('EAC'). Equal
volumes of EA nb were used at a concentration of 1 x 108 red blood cells/ml. The dilution of fresh
serum was adjusted to give between 20 and 30% monocyte rosettes and was usually between 1 in 600
and 1 in 1,000.
Monocytes. Blood from healthy donors was drawn into plastic tubes containing 10 units of
preservative-free heparin/ml. Monocytes were separated on Ficoll-Hypaque cushions according to
the method of Boyum (1968). The separated cells were washed twice in Dulbecco's PBS (modified)
(pH 7 2-7 4), containing preservative-free heparin (2 units/ml) and resuspended in medium 199, pH
7 4, to a concentration of 1 x 106 monocytes,/ml.
Complement (EAC) and IgG (EAG) rosettes and rosette enhancement. For the experiments
described in Table 2 equal volumes of monocytes (1 x 106/ml) and various concentrations of casein
or medium alone were mixed and incubated in a shaking water bath, usually at 37°C for 30 min. The
cells were then washed twice in medium 199 and the numbers readjusted to their original concentra-
tion in the same medium. A portion (0 1 ml) ofEAC or EAG (1 x 108/ml) was added to 0 1 ml of cells
Table 1. Histological features of undifferentiated, squamous and adenocarcinomas from human lung
Accompanying histological features
Chronic
Viable Fibrous inflammatory
Patient Necrosis tumour tissue PMNs cells
Undifferentiated
1. Largecell + + + + 0 +
2. Largecell + + + + + + +
3. Smallcell + + + ++ 0 +
4. Smallcell + + + + 0 +
Squamous
5. Moderately well
differentiated + + + + + +
6. Poorly differentiated + + + + + +
7. Poorly differentiated + + + + + + +
8. Poorly differentiated + + + + + + + +
Adenocarcinoma
9. Well differentiated + ++ + + + +
10. Poorly differentiated + + + + + +
11. Moderately well
differentiated 0 ++ + ++ 0 0
0= Nil; ± = very slight; + = slight; + + = moderate; + + + = marked. The
tumour type was assessed independently by two histopathologists.
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Table 2. Enhancement of monocyte complement rosettes by casein
Rosettes (%)
'EAC' EAM1423b EA0
Medium 199 25+4 23+1 30+3
Casein
1 mg/ml 34+5 35+1 31+4
2 mg/ml 42+2 41+2 30+4
3 mg/ml 48 +6 46+2 34+ 5
Red cell intermediates were sensitized with
IgM and prepared either with whole serum
('EAC') as a source of complement or with
purified components (EAM1423b) or with IgG
(EAG). The results represent the mean + 1
s.e.m. of three experiments.
and centrifuged at lOOg for 10 min at 40C and the pellets incubated at 37 C for 20 min for EAC and
00C for 30 min in the preparation of EAG. The pellet was gently resuspended in medium 199
containing 1% formal-saline and smears prepared on clean glass slides in duplicate. These were
dried quickly in air, fixed in methanol and stained with May-Griinwald/Giemsa or fixed in 255%
glutaraldehyde and stained using a-naphthyl acetate histochemistry according to the method of
Yam, Li & Crosby (1971). Comparison of these two methods by four independent observers
revealed no statistical significance in differentiating monocytes from lymphocytes.
Inhibition of casein-induced enhancement by tumour or normal lung homogenates. Monocytes
were prepared as described above and divided into 14 portions of 0-1 ml each containing 1 x 10I
monocytes/ml. The experimental design is shown in Fig. 1. Two tubes were required for 'enhance-
ment by casein alone' [(B - C/C) x 100] and this was performed as described for Table 2 (but with
the addition of a 30-min incubation period at 37°C, after which the cells were centrifuged (300g for
10 min at 4°C) prior to the addition of 0 1 ml of medium 199 (C) or casein (B) - Fig. 1). Monocyte
suspensions were also incubated with dilutions of tumour extract (25 ,g protein/ml - two tubes, 50
yg/ml - two tubes, 100 Mg/ml - two tubes) and normal lung homogenates (25 Pg protein/ml - two
tubes, 50 yg/ml - two tubes, 100 yg/ml - two tubes). Three of the monocyte preparations treated
with tumour extract (i.e. 25, 50 and 100 pg/ml) and three treated with normal lung (i.e. 25, 50 and
100 pg/ml) were then incubated with either medium 199 or casein (3 mg/ml). Enhancement, and
enhancement-inhibition were calculated as described in Fig. 1.
Gel filtration. Samples (0-75 ml) of either tumour or normal lung extract were applied to a
column of Sephadex G-50 (1-5 x 100 cm). The column was calibrated with molecular markers (blue
dextran, cytochrome c and vitamin B12) in phosphate-buffered saline (pH 7 2) and 1-ml fractions
collected. Every third fraction was tested for inhibition of casein-induced monocyte complement
receptor enhancement using 0 l-ml amounts as described in Fig. 1.
RESULTS
Enhancement ofcomplement rosettes
The capacity of casein, a recognized monocyte leucoattractant, to enhance the percentage of
monocyte C3b rosettes is shown in Table 2. The effect was dose-dependent and demonstrable when
either 'EAC' or EAM1423b were used as indicator erythrocytes. In contrast, there was a small but
statistically insignificant increase in the percentage of EAG (Fc) rosettes. When expressed as a
percentage increase, enhancement of Fc receptors by the highest dose of casein was only 13%
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Monocytes + Monocytes + Monocytes +
mediumts199 dilutions () of dilutions (x3)ofmedium 199 dilutions (x3) of normal lung
I tu r h nt homogenate
Incubate for 30 min at 370C,
centrifuge aInd resuspend
Two treatments Two treatments
Medium 199 (C) Casein (B) Medium 199 (D) Casein (A)
Incubate for 30 min at 370C, centrifuge and resuspend
Add 'EAC' , centrifuge, incubate for 20 min at 370C
Count rosettes (0/)
Enhancement by casein alone = B-C x 100
C-
Enhancement by tumour or normal lung alone = c-- x 100
C~~~~~~AC
Inhibition of casein-induced enhancement by tumour or normal lung = 100 - (B C) x 100
Fig. 1. Schematic outline of the methodology for monocyte complement receptor enhancement and enhance-
ment inhibition by tumour and normal lung homogenates.
whereas with 'EAC' or EAMl423b the increases were 92 and 100% respectively. Because of the
similar results obtained using either 'EAC' or EAM1423b in terms of the dose response by casein
(and also, as reported elsewhere, as a function of time (Glass & Kay, 1980)) for convenience 'EAC'
were used as indicator cells in further experiments.
Inhibition ofenhancement
A dialysable extract from a homogenate of an adenocarcinoma of the bronchus was tested both for
its effect on the percentage of monocyte complement rosettes and for its capacity to inhibit
casein-induced monocyte complement receptor enhancement. The tumour extract, at concentra-
tions of 25, 50 and 100 pg protein/ml, was compared with microscopically normal lung from the
same resected specimen. Neither the tumour homogenate (TH) nor the normal lung homogenate
(NLH) significantly influenced the percentage of rosettes with 'EAC'. In contrast, the TH inhibited
casein-induced enhancement in a dose-dependent fashion which at the highest concentration (100
pg protein/ml) was significantly different from NLH (P < 0 05).
The time course of inhibition enhancement by TH and NLH from another adenocarcinoma of
the bronchus is shown in Fig. 2. The percentage increase was maximal at 30 min with no further
inhibition being observed up to 2 hr at which time the experiment was terminated. Inhibition by
NLH was considerably less and when expressed as the mean of three experiments was virtually
negligible.
Various histological types
Undifferentiated. The effect ofTH and NLH from four patients with undifferentiated carcinoma
of the bronchus on monocyte complement rosettes and casein-induced enhancement is shown in
Fig. 3. The percentage enhancement of the normal donor monocytes by casein was comparable to
that achieved in the experiments described in Table 2. Both TH and NLH promoted some
complement receptor enhancement per se although the differences between them, at the three
concentrations tested, were not significant. Furthermore, the dose-response with NLH was 'flat'
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Fig. 2. The time course of inhibition of leucoattractant-induced enhancement of monocyte complement
receptors by tumour and normal lung homogenates. Each point represents the mean + 1 s.e.m. of three
experiments and the experimental design is shown in Fig. 1. The material was derived from an adenocarcinoma
of lung.
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Fig. 3. Inhibition of leucoattractant-induced enhancement of monocyte complement rosettes by homogenates
from various lung cancers. (.) Tumour and (o) normal lung homogenate. Each point represents the mean + 1
s.e.m. of four undifferentiated tumours, four squamous and three adenocarcinomas of lung. The P values were
calculated from Student's t-test. The experimental design is outlined in Fig. 1.
and with TH there was apparent inhibition at higher doses. In contrast, TH when compared to
NLH gave significant inhibition ofcasein-induced enhancement at the highest concentration tested.
The inhibitory effect ofTH increased in proportion to the concentration ofTH. Some inhibition of
enhancement was observed with NLH but the dose-response was not linear, less effect being
observed at 100 pg than with 50 pg protein/ml. The individual data (not shown) indicate that
although there was considerable variation in the amount of inhibition achieved by the four
undifferentiated tumours, the general pattern of increased enhancement inhibition by TH, as
compared to NLH, was sustained.
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Squamous. Comparable results were obtained with four squamous carcinomas of the bronchus
(Fig. 3). With these tumours the difference between TH and NLH in terms of their effects on
receptors per se was negligible although with both materials there was a slight increased percentage
change from control but this did not appear to be related to the concentration of the extracts. By
contrast, inhibition of casein-induced enhancement by these tumour extracts increased with dose
and, at both the 50 and 100 pg concentrations, was significantly different from NLH. NLH from the
squamous tumour resections gave very little enhancement-inhibition, even at the higher concentra-
tions.
Adenocarcinoma. Three adenocarcinomas of the bronchus were tested in a comparable manner
(Fig. 3). The NLH from these resections gave a dose-dependent increase in monocyte complement
rosettesper se, but the effects were not significantly different from TH. With enhancement-inhibition
there was a marked and statistically significant difference between TH and NLH at the 50 and 100
pg protein concentrations. The individual results (not shown) indicate that the variations in
observed effects were wide, but the general pattern of dose-dependent inhibition of casein-induced
enhancement by TH, as compared to NLH, was sustained.
Gelfiltration ofhomogenates
TH and NLH from one undifferentiated (patient 1), one squamous (patient 5) and one adenocar-
cinoma (patient 11) were passed separately through a column of Sephadex G-50, previously
calibrated with molecular markers. Fractions were tested for inhibition of enhancement as de-
scribed in the methodology (Fig. 4).
Virtually all the fractions tested, irrespective of whether they were TH- or NLH-derived, gave
inhibition of enhancement although in some the values were below zero. Because of the high
'background' activity with the normal lung homogenates only those peaks having maximal
enhancement-inhibition of40% or more were considered as having appreciable biological activity.
Using this 'cut-off' point it could be seen that with the undifferentiated tumour there were two peaks
of activity ofapproximately 3,000 and 8,000 daltons respectively. The squamous tumour also had a
Blue dextran Cytochrome c Vitamin B12
(2x106) (12,270) (1,357)
t t Undifferentiated60 *. *
40- / /\ Tumour
20
.
.0.0 ...
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-
No~~*.q2
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o
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Squamous60_
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o
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Fig. 4. Sephadex G-50 gel filtration ofhomogenates from lung cancer and normal lung. The points are the mean
of three assays of inhibition of leucoattractant-induced enhancement.
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peak at 3,000 and the adenocarcinoma had inhibitory activities at 3,000 and 10,000 daltons
approximately. Thus all three tumour types had a peak molecular weight at 3,000 and the
undifferentiated and adenocarcinoma had activities between 8,000-10,000 daltons. NLH from each
tumour type did not give peaks of greater than 35% and in most measurements it was less than 20%
enhancement-inhibition.
DISCUSSION
The main purpose of the experiments reported here was to determine whether factors derived from
human lung cancer affected leucoattractant-mediated increase in complement receptor 'density' of
blood monocytes from healthy individuals. Although we have provided evidence for the presence of
such inhibitory principles we cannot say with certainty whether they are tumour-associated or
tumour-derived. It is of note that there did not appear to be an association between the degree of
inhibition and the histological features of the tumours (Table 1). For example, tumour nos. 3, 4 and
11 had little or no associated chronic inflammatory cells or infiltration with polymorphonuclear
leucocytes but they all gave considerable inhibition of enhancement of complement receptors.
Similarly, tumour nos. 2 and 11 had little or no necrosis but considerable inhibitory activity could be
derived from the tumour mass. Thus the inhibitory properties of the tumour dialysate would not
appear to be directly attributable to the degree of acute and chronic inflammation, necrosis or
fibrosis associated with the neoplastic lesion.
We have so far only examined the effect of TH on casein-induced complement receptor
enhancement on the blood monocyte and are unable to say whether a similar effect would be
demonstrable (a) with other blood leucocytes such as neutrophils and eosinophils and (b) with other
appropriate C-receptor-enhancing chemoattractants. Because of limitations in the supply of
tumour extract we felt that priority should be given to preliminary studies on the possible
heterogeneity of the activities as assessed by gel filtration chromatography. As shown in Fig. 4 each
tumour contained at least two peaks of inhibitory activity although NLH did not give inhibition of
> 40%. Taking 40% inhibition as a reasonable cut-off point it can be seen that the only substantial
peaks of inhibitory activity are in the tumour extracts. All three tumour types shared one peak
which eluted just before the vitamin B12 molecular marker and had an estimated molecular size of
3,000 daltons. The undifferentiated and adenocarcinoma tumour extracts both had a higher peak of
inhibitory activity at approximately 8,000-10,000 daltons. The squamous tumour also had a peak
at 8,000-10,000 daltons but maximal activity was just > 40%. This aspect of the study clearly
requires expansion to include more detailed protein-separation techniques.
It is generally agreed that there is no clear association between clinical prognosis and the
histological types of various forms of lung cancer. There was no evidence from the present study
that the degree of inhibitory activity was related to the histological type.
There is formidable literature on the relation between macrophages and cancer and, as men-
tioned in the Introduction, there are a number of animal studies which support the view that
tumours elaborate anti-macrophage material. Snyderman and his colleagues reported that mouse
tumours inhibited macrophage mobilization in the peritoneal cavity and that a number ofcell lines
produce a factor of molecular weight between 6,000-10,000 daltons which inhibits macrophage
chemotaxis in vitro (Pike & Snyderman, 1976; Snyderman & Pike, 1976). The agent was heat-stable
and had peak inhibitory activity 3 days after administration. When the factor was injected together
with tumour cells into syngeneic mice there was an increase in tumour dissemination when
compared to the effect of the tumour alone. Fauve et al. (1974) have demonstrated that mouse
teratocarcinoma and other tumour cells in culture elaborate a factor of between 1,000 and 10,000
which inhibits local inflammation in vivo, and these same cells in vitro were found to prevent direct
contact by normal peritoneal macrophages. Nelson & Nelson (1978) have described a similar factor
produced by murine fibrosarcoma cells which depressed delayed-type hypersensitivity reactions in
vivo and inhibited macrophage chemotaxis in vitro. It is believed to be glycopeptide in nature and
associated with an RNA fragment. North et al. (1976) reported that in the serum oftumour-bearing
mice there was a dialysable factor which depressed macrophage-mediated resistance to infection.
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In the present report we have described low molecular weight material derived from human lung
cancers which inhibits leucoattractant-induced enhancement of complement receptors on normal
human monocytes and in this respect may be analogous to factors described in animals which
depress macrophage function. Further studies are required to characterize these principles more
fully and to explore the possibility that active immunity to them may have therapeutic potential.
This work was supported by the Cancer Research Campaign.
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